Intravenous Synthetic Cannabidiol

About Isosceles Pharmaceuticals

Isosceles Pharmaceuticals is a private, preclinical-stage biotech founded in 2019, targeting the massive and growing acute pain market with intravenous and intradermal formulations of synthetic cannabidiol. The company's strategy centers on bypassing first-pass metabolism via parenteral delivery to achieve fast onset and high bioavailability, positioning its candidates as potential alternatives to addictive opioids. Led by a team with extensive experience in pain product development, Isosceles is operating in a high-need area driven by the opioid epidemic and increasing surgical volumes, though it faces significant development and regulatory risks common to early-stage drug developers.

Therapeutic Areas